Ascendis Pharma AS (A71) - Net Assets
Based on the latest financial reports, Ascendis Pharma AS (A71) has net assets worth €-162.82 Million EUR (≈ $-190.35 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.30 Billion ≈ $1.52 Billion USD) and total liabilities (€1.47 Billion ≈ $1.71 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check A71 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-162.82 Million |
| % of Total Assets | -12.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | -118.43% |
| 10-Year Change | N/A |
| Growth Volatility | 81.08 |
Ascendis Pharma AS - Net Assets Trend (2016–2025)
This chart illustrates how Ascendis Pharma AS's net assets have evolved over time, based on quarterly financial data. Also explore Ascendis Pharma AS total assets for the complete picture of this company's asset base.
Annual Net Assets for Ascendis Pharma AS (2016–2025)
The table below shows the annual net assets of Ascendis Pharma AS from 2016 to 2025. For live valuation and market cap data, see A71 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-162.82 Million ≈ $-190.35 Million |
-54.03% |
| 2024-12-31 | €-105.71 Million ≈ $-123.58 Million |
+27.45% |
| 2023-12-31 | €-145.70 Million ≈ $-170.34 Million |
-155.32% |
| 2022-12-31 | €263.35 Million ≈ $307.88 Million |
-70.20% |
| 2021-12-31 | €883.63 Million ≈ $1.03 Billion |
+5.36% |
| 2020-12-31 | €838.71 Million ≈ $980.54 Million |
+40.46% |
| 2019-12-31 | €597.11 Million ≈ $698.09 Million |
+113.22% |
| 2018-12-31 | €280.05 Million ≈ $327.41 Million |
+49.59% |
| 2017-12-31 | €187.21 Million ≈ $218.87 Million |
+6.00% |
| 2016-12-31 | €176.61 Million ≈ $206.48 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ascendis Pharma AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 13931300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Total Equity | €-162.82 Million | 100.00% |
Ascendis Pharma AS Competitors by Market Cap
The table below lists competitors of Ascendis Pharma AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Toll Brothers Inc
NYSE:TOL
|
$13.24 Billion |
|
ARC Resources Ltd.
TO:ARX
|
$13.26 Billion |
|
Bharat Heavy Electricals Limited
NSE:BHEL
|
$13.27 Billion |
|
Focus Media Information Technology Co Ltd
SHE:002027
|
$13.29 Billion |
|
YPF Sociedad Anónima
F:YPF
|
$13.22 Billion |
|
The Siam Commercial Bank Public Company Limited
BK:SCB-R
|
$13.22 Billion |
|
NAT.B.GR. SPONS.ADR/1
F:NAG
|
$13.22 Billion |
|
Sociedad Química y Minera de Chile S.A.
SN:SQM-B
|
$13.22 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ascendis Pharma AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -105,706,000 to -162,821,000, a change of -57,115,000.
- Net loss of 228,034,000 reduced equity.
- Share repurchases of 17,396,000 reduced equity.
- Other factors increased equity by 188,315,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-228.03 Million | -140.05% |
| Share Repurchases | €17.40 Million | -10.68% |
| Other Changes | €188.31 Million | +115.66% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Ascendis Pharma AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €5.06 | €206.00 | x |
| 2018-12-31 | €6.65 | €206.00 | x |
| 2019-12-31 | €12.44 | €206.00 | x |
| 2020-12-31 | €15.60 | €206.00 | x |
| 2021-12-31 | €15.52 | €206.00 | x |
| 2022-12-31 | €4.61 | €206.00 | x |
| 2023-12-31 | €-2.57 | €206.00 | x |
| 2024-12-31 | €-1.77 | €206.00 | x |
| 2025-12-31 | €-2.65 | €206.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ascendis Pharma AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.67%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-50.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -38.79% | -1487.30% | 0.02x | 1.08x | €-86.17 Million |
| 2017 | -66.18% | -8097.84% | 0.01x | 1.13x | €-142.62 Million |
| 2018 | -46.45% | -1229.53% | 0.03x | 1.14x | €-158.10 Million |
| 2019 | -36.51% | -1630.03% | 0.02x | 1.13x | €-277.73 Million |
| 2020 | -49.95% | -6025.53% | 0.01x | 1.17x | €-502.83 Million |
| 2021 | -43.41% | -4931.56% | 0.01x | 1.23x | €-471.94 Million |
| 2022 | -221.45% | -1139.63% | 0.05x | 4.14x | €-609.53 Million |
| 2023 | 0.00% | -180.51% | 0.32x | 0.00x | €-466.88 Million |
| 2024 | 0.00% | -103.97% | 0.31x | 0.00x | €-367.51 Million |
| 2025 | 0.00% | -31.67% | 0.55x | 0.00x | €-211.75 Million |
Industry Comparison
This section compares Ascendis Pharma AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,057,695,497
- Average return on equity (ROE) among peers: -39.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ascendis Pharma AS (A71) | €-162.82 Million | -38.79% | N/A | $13.23 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $209.51 Million | -46.30% | 0.68x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $2.05 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $3.43 Billion | -0.21% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more